Related Experiment Videos
Cost-benefit of treating hypertension
1Centre for Health Economics, Stockholm School of Economics, Sweden.
Summary
Treating hypertension is cost-effective for most adults with high blood pressure (≥ 90 mmHg). Adding other risk factors further improves treatment cost-effectiveness, making it a valuable public health intervention.
Area of Science:
- Cardiovascular Medicine
- Health Economics
- Public Health Policy
Background:
- Hypertension is a major global health concern, necessitating effective and economically viable treatment strategies.
- Previous studies have explored the costs and benefits of hypertension management, but updated estimates considering various patient demographics are crucial.
Purpose of the Study:
- To conduct a comprehensive review of existing literature on the costs and benefits associated with hypertension treatment.
- To generate novel estimates of the cost-effectiveness of antihypertensive therapies, stratified by patient age, sex, and blood pressure levels.
Main Methods:
- Economic evaluation of various antihypertensive drug classes.
- Cost-effectiveness measured as cost per life-year gained, based on documented risk reductions from interventions.
- Extensive sensitivity analysis using Swedish cost data and literature-derived clinical effect assumptions.
Main Results:
- Antihypertensive treatment is generally cost-effective for individuals with a diastolic blood pressure of 90 mmHg or higher.
- Treatment is less cost-effective for patients younger than 45 years.
- The presence of additional cardiovascular risk factors significantly enhances the cost-effectiveness of treatment.
Conclusions:
- Economic evaluation supports the cost-effectiveness of treating hypertension in most adult populations.
- Targeted treatment strategies, considering age and comorbidities, are essential for optimizing resource allocation in hypertension management.